Advanced Search

The story appears on

Page A7

October 17, 2015

GET this page in PDF

Free for subscribers

View shopping cart

Related News

Home » Business » Finance

HK drug firm seeks to list on Nasdaq

Source: Agencies | October 17, 2015, Saturday | Print Edition

HONG Kong-based drugmaker Hutchison China MediTech Ltd has filed for an initial public offering in the United States, according to a regulatory filing.

The London-listed biopharmaceutical company, majority owned by Chinese conglomerate CK Hutchison Holdings Ltd, is also known as Chi-Med.

Far fewer Chinese companies have listed in the US so far this year than in 2014.

The US IPOs of two Chinese companies raised about US$150 million this year to June. In the corresponding period last year, the listing of 10 Chinese companies in the United States had raised over US$3.5 billion, according to Thomson Reuters data.

Hutchison China, founded in 2000 by Hutchison Whampoa Ltd, makes cancer and arthritis drugs and medical devices.

The company, which listed on the London Stock Exchange in 2006, has seven drug candidates in clinical-stage trials, three of which it is developing with units of AstraZeneca Plc, Eli Lilly & Co and Nestle SA.

Four of these drug candidates are for tumors and one each for lung cancer and rheumatoid arthritis.

Five of the seven drug candidates could be eligible for accelerated approval by the US Food and Drug Administration, Hutchison China said in a filing to the US Securities and Exchange Commission.

Hutchison China’s revenue more than doubled to US$87.3 million in 2014.

The firm plans to list on Nasdaq under the symbol “HCM.” It has set a target of up to US$100 million for the IPO, according to the filing.

BusinessFinanceHKNasdaq


 

Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend